SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-PI-LPS [1E4] Bulk Size Ab03230-2.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Mouse IgG2a, Fc Silent™, Kappa
Clone Number: 1E4
Alternative Name(s) of Target: phase I lipopolysaccharide; LPS phase I; C. burnetii PI-LPS; C. burnetii phase I lipopolysaccharide
UniProt Accession Number of Target Protein:
Published Application(s): in vitro, in vivo, WB, ELISA
Published Species Reactivity: C. burnetii
Immunogen: The original antibody was generated by immunizing BALB/c mice with formalin-inactivated C. burnetii Nine Mile PI antigen.
Specificity: The antibody recognizes a PI specific epitope on PI-LPS. The antibody does not cross react with PII-LPS.
Application Notes: The specificity of the antibody (IgG2a) for PI-LPS was confirmed by ELISA analysis. The antibody detected PI-LPS by western blot analysis. The antibody was able to inhibit C. burnetii infection in vivo in a dose-dependent manner (Peng et al., 2012; PMID: 23053512). The original antibody could confer protection against C. burnetii aerosol infection. The Fab fragment, the scFv fragment and the humanized version of the antibody were constructed and characterized by indirect ELISA and Western Blot. They were able to bind to C. burnetii and to inhibit the infection in mice and in mouse Bone Marrow-Derived Macrophages (BMDM) in vitro. The humanized version inhibited C. burnetii infection in human macrophages in vitro. The Fab fragment was able to neutralize virulent C. burnetii resulting in inhibiting C. burnetii infection in both in vitro and in vivo systems (US20150087807A1). The ability of the original antibody, Fab, scFv, and humanized version of the antibody to inhibit C. burnetii infection in vivo was evaluated by comparing splenomegaly, bacterial burden, and pathological changes in the spleen with control mice at 14 days postinfection. IFA was used to analyze the ability of the original antibody to bind live virulent C. burnetii. The ability of the original to inhibit C. burnetii was higher than the ability of the other fragments. The humanized version of the antibody showed potential as a therapeutic against C. burnetii exposure (Peng et al., 2014; PMID: 25114119).
Antibody First Published in: Peng et al. Development of a lipopolysaccharide targeted peptide mimic vaccine against Q fever. J Immunol. 2012 Nov 15; 189(10): 10.4049/jimmunol.1201622. PMID:23053512
Note on publication: The paper describes the generation and characterization of the antibody.

Product Form

Size: 1 mg Purified antibody in bulk size.
Purification: Protein A affinity purified
Supplied In: PBS only.
Storage Recommendation: Store at 4^{o}C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer

storage, aliquot and store at -20ºC.
Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.